Cannabidivarin, also known has CBDV, is a non-intoxicating rare cannabinoid that was first isolated in 1969. CBDV may share a similar name to its well-known cousin cannabidiol, or CBD, but unlike CBD, CBDV is a minor cannabinoid and has demonstrated unique physiological effects. CBDV has a similar molecular structure to CBD but with two fewer carbon atoms on its sidechain.
CBDV is one of the most studied rare cannabinoids and has been researched for a myriad of conditions and physiological effects.
Cannabidivarin is a rare cannabinoid
Unlike well-known cannabinoids tetrahydrocannabinol (THC) and cannabidiol (CBD) which are abundant in the plant, CBDV is known as a minor cannabinoid and is found in miniscule quantities in the plant, making them difficult and cost-prohibitive to extract directly from the plant. Rare cannabinoids are an emerging class of compounds which are gaining interest for their potential medical benefits.
Modern technologies in cannabinoid manufacturing, such as biosynthesis and chemical synthesis, both of which are used by BayMedica, have enabled production of these rare cannabinoids at commercial quantities, making them cost-effective as raw ingredients for various applications.
Cannabidivarin interacts with many cannabinoid receptors of the endocannabinoid system
Scientific literature suggests that CBDV acts as an agonist of TRPA1, TRPV1 and TRPV2 receptors, an inverse agonist of GPR6, an antagonist of GPR55and may be an inhibitor of endocannabinoid 2-AG production. CBDV is reported to have a low affinity for CB1 receptors and there is conflicting research on CBDV’s binding affinity for CB2 receptors.
Cannabidivarin has been studied for various conditions
Although research into minor cannabinoids is only emerging in the last few years, CBDV is one of the most studied rare cannabinoids and has been researched for several conditions and physiological effects.
Cannabidivarin is being studied in clinical trials
Currently, there is no regulatory approval of CBDV for therapeutic use for any condition. CBDV has been the subject of clinical trials in a number of conditions which can be found on the clinical trials website.
Learn more about CBDV
CBDV is one of several rare cannabinoids manufactured by BayMedica. Our CBDV is produced to greater than 95% purity via a proprietary process. Our cannabinoids are made in accordance with food-grade GMP standards, and are tested at certified laboratories.
Learn more about the scientific research into CBDV. You can sign up here to learn more information about CBDV.